Innate Pharma (IPHA) Receivables - Other (2017 - 2025)

Innate Pharma (IPHA) has disclosed Receivables - Other for 8 consecutive years, with $770457.3 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Receivables - Other rose 588.54% year-over-year to $770457.3, compared with a TTM value of $770457.3 through Dec 2024, up 588.54%, and an annual FY2024 reading of $780365.9, up 593.67% over the prior year.
  • Receivables - Other was $770457.3 for Q4 2024 at Innate Pharma, up from $111897.8 in the prior quarter.
  • Across five years, Receivables - Other topped out at $931192.4 in Q4 2021 and bottomed at $62235.1 in Q4 2022.
  • Average Receivables - Other over 5 years is $551853.9, with a median of $770457.3 recorded in 2024.
  • The sharpest move saw Receivables - Other tumbled 93.32% in 2022, then soared 588.54% in 2024.
  • Year by year, Receivables - Other stood at $883486.8 in 2020, then rose by 5.4% to $931192.4 in 2021, then crashed by 93.32% to $62235.1 in 2022, then surged by 79.8% to $111897.8 in 2023, then skyrocketed by 588.54% to $770457.3 in 2024.
  • Business Quant data shows Receivables - Other for IPHA at $770457.3 in Q4 2024, $111897.8 in Q4 2023, and $62235.1 in Q4 2022.